PaxMedica Announces NASDAQ Closing Bell Ringing to Celebrate Initial Public Offering and Autism Awareness Month
Broadcasting Live on Wednesday April 19th at 3:45 PM ET TARRYTOWN, NY, April 19, 2023…
Month: April 2023
PaxMedica Announces NASDAQ Closing Bell Ringing to Celebrate Initial Public Offering and Autism Awareness Month
Broadcasting Live on Wednesday April 19th at 3:45 PM ET TARRYTOWN, NY, April 19, 2023…
Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions 2023 in June
New clinical data from COVALENT-111 will be featured during the Late-Breaking Poster Presentations at the…
Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions 2023 in June
New clinical data from COVALENT-111 will be featured during the Late-Breaking Poster Presentations at the…
Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico
BASKING RIDGE, NJ, April 19, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico
BASKING RIDGE, NJ, April 19, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today
ZUG, Switzerland, April 19, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology…
MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today
ZUG, Switzerland, April 19, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology…
Panbela Announces Poster Presentation at American Association for Cancer Research: Evaluating the potential of spermine analogue ivospemin (SBP-101) in combination with chemotherapy in ovarian cancer
MINNEAPOLIS, April 19, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage…
Panbela Announces Poster Presentation at American Association for Cancer Research: Evaluating the potential of spermine analogue ivospemin (SBP-101) in combination with chemotherapy in ovarian cancer
MINNEAPOLIS, April 19, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage…
Revolo Biotherapeutics Announces Positive Topline Data from Phase 2a Trial of ‘1104 in Adults with Active Eosinophilic Esophagitis
– Data shows achievement of primary endpoint of decreasing esophageal intraepithelial eosinophil count and positive…
Revolo Biotherapeutics Announces Positive Topline Data from Phase 2a Trial of ‘1104 in Adults with Active Eosinophilic Esophagitis
– Data shows achievement of primary endpoint of decreasing esophageal intraepithelial eosinophil count and positive…
Keros Therapeutics Appoints Alpna Seth, Ph.D., to its Board of Directors
LEXINGTON, Mass., April 19, 2023 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”)…
Keros Therapeutics Appoints Alpna Seth, Ph.D., to its Board of Directors
LEXINGTON, Mass., April 19, 2023 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”)…
Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2023 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:…
Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2023 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:…
VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis
VYN201 at the 0.5 mg/ml and 1 mg/ml doses demonstrated statistically significant reductions in lung…
VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis
VYN201 at the 0.5 mg/ml and 1 mg/ml doses demonstrated statistically significant reductions in lung…
Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting
BOSTON, April 19, 2023 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage…
Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting
BOSTON, April 19, 2023 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage…